Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences has received regulatory approval from DCGI to begin Phase III clinical trials for Zintrodiazine, a novel anti-malarial drug candidate. The company will conduct two separate trials covering 1,041 patients total—one trial on 651 patients with uncomplicated P. falciparum malaria and another on 390 patients with P. vivax malaria. Both trials are multi-centre, randomised, assessor-blind studies evaluating efficacy, safety, and tolerability against active comparators. Zintrodiazine targets all clinical strains including drug-resistant variants, addressing the growing threat of artemisinin resistance globally. The drug is being developed in partnership with Medicines for Malaria Venture (MMV) since 2016 as a potential alternative to current front-line artemisinin-based combination therapies.
Positive development for shareholders as it marks significant clinical advancement with Phase III entry, representing the final stage before potential regulatory approval. Success could open a substantial market given malaria affects over 180,000 people annually in India and resistance to existing therapies is growing.